Search - tctmd.com

Displaying 221 - 240 of 396

Sort: Relevancy | Date

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

News Daily News

Open Questions: Cardiology Editors and Academics Mull Data-Sharing Pitfalls and Potential

Shelley Wood

July 04, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Daily News

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Yael L. Maxwell

June 25, 2018

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

Todd Neale

June 25, 2018

Will Percutaneous Mitral Repair Catch Up or Surpass Surgery? Experts Make Their Predictions

Shelley Wood

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Will the Randomized Trials of MitraClip in Secondary MR Show Substantial Clinical Benefit? YES!

Presenter: Scott Lim

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Will the Randomized Trials of MitraClip in Secondary MR Show Substantial Clinical Benefit? NO!

Presenter: Francesco Maisano

June 22, 2018

News Conference News The Structural Heart Disease Summit 2018

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Shelley Wood

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Presenter: Lars Sondergaard

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

UK All-Comers

Presenter: Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Partner 3 Low-Risk

Presenter: Martin B. Leon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Keystone TRIGUARD Cerebral Embolic Protection During TAVR: New Generation Devices and the Status of Ongoing Clinical Trials

Presenter: Eberhard Grube, Tamim Nazif

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Presenter: George D. Dangas

June 21, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

News Daily News

Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: Some Successes, Some Caveats

Shelley Wood

June 18, 2018

Advertisement

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

New Review Probes Possibility of CVD Prevention Without Aspirin

Open Questions: Cardiology Editors and Academics Mull Data-Sharing Pitfalls and Potential

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Once Again, ISCHEMIA Trial Feels the Squeeze

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

Will Percutaneous Mitral Repair Catch Up or Surpass Surgery? Experts Make Their Predictions

Will the Randomized Trials of MitraClip in Secondary MR Show Substantial Clinical Benefit? YES!

Will the Randomized Trials of MitraClip in Secondary MR Show Substantial Clinical Benefit? NO!

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

UK All-Comers

Evolut R Low-Risk

Partner 3 Low-Risk

Keystone TRIGUARD Cerebral Embolic Protection During TAVR: New Generation Devices and the Status of Ongoing Clinical Trials

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: Some Successes, Some Caveats

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content